Avalo Therapeutics AVTX Stock
Avalo Therapeutics Price Chart
Avalo Therapeutics AVTX Financial and Trading Overview
| Avalo Therapeutics stock price | 16.18 USD |
| Previous Close | 16.12 USD |
| Open | 16.43 USD |
| Bid | 11.8 USD x 200 |
| Ask | 16.29 USD x 100 |
| Day's Range | 16.12 - 16.53 USD |
| 52 Week Range | 9.54 - 24.27 USD |
| Volume | 281.93K USD |
| Avg. Volume | 1.24M USD |
| Market Cap | 871.49M USD |
| Beta (5Y Monthly) | 0.793 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.41 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 44.08 USD |
AVTX Valuation Measures
| Enterprise Value | 464.48M USD |
| Trailing P/E | N/A |
| Forward P/E | -5.9258556 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 14770.971 |
| Price/Book (mrq) | 1.9160477 |
| Enterprise Value/Revenue | 7872.566 |
| Enterprise Value/EBITDA | -5.09 |
Trading Information
Avalo Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.793 |
| 52-Week Change | 58.97% |
| S&P500 52-Week Change | 15.74% |
| 52 Week High | 24.27 USD |
| 52 Week Low | 9.54 USD |
| 50-Day Moving Average | 19.06 USD |
| 200-Day Moving Average | 16.92 USD |
AVTX Share Statistics
| Avg. Volume (3 month) | 1.24M USD |
| Avg. Daily Volume (10-Days) | 996.17K USD |
| Shares Outstanding | 53.63M |
| Float | 40.11M |
| Short Ratio | 16.4 |
| % Held by Insiders | 1.68% |
| % Held by Institutions | 133.42% |
| Shares Short | 12.39M |
| Short % of Float | 23.12% |
| Short % of Shares Outstanding | 23.10% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:240 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -154847.45% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -18.49% |
| Return on Equity (ttm) | -36.27% |
Income Statement
| Revenue (ttm) | 59K USD |
| Revenue Per Share (ttm) | 0.002 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | -47893000 USD |
| EBITDA | -91251000 USD |
| Net Income Avi to Common (ttm) | -100333000 USD |
| Diluted EPS (ttm) | -4.41 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 400.28M USD |
| Total Cash Per Share (mrq) | 7.46 USD |
| Total Debt (mrq) | 242K USD |
| Total Debt/Equity (mrq) | 0.05 USD |
| Current Ratio (mrq) | 19.306 |
| Book Value Per Share (mrq) | 8.481 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -68290000 USD |
| Levered Free Cash Flow (ttm) | -23271000 USD |
Profile of Avalo Therapeutics
| Country | United States |
| State | PA |
| City | Wayne |
| Address | 1500 Liberty Ridge Drive |
| ZIP | 19087 |
| Phone | 410 522 8707 |
| Website | https://www.avalotx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 33 |
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.
Q&A For Avalo Therapeutics Stock
What is a current AVTX stock price?
Avalo Therapeutics AVTX stock price today per share is 16.18 USD.
How to purchase Avalo Therapeutics stock?
You can buy AVTX shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Avalo Therapeutics?
The stock symbol or ticker of Avalo Therapeutics is AVTX.
Which industry does the Avalo Therapeutics company belong to?
The Avalo Therapeutics industry is Biotechnology.
How many shares does Avalo Therapeutics have in circulation?
The max supply of Avalo Therapeutics shares is 53.63M.
What is Avalo Therapeutics Price to Earnings Ratio (PE Ratio)?
Avalo Therapeutics PE Ratio is now.
What was Avalo Therapeutics earnings per share over the trailing 12 months (TTM)?
Avalo Therapeutics EPS is -4.41 USD over the trailing 12 months.
Which sector does the Avalo Therapeutics company belong to?
The Avalo Therapeutics sector is Healthcare.
Avalo Therapeutics AVTX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
26186.41 USD — |
-0.56
|
6.24B USD — | 25992.55 USD — | 26329.98 USD — | — - | 6.24B USD — |
|
US Tech Health Care
IXHC
US
|
1308.52 USD — |
+1.15
|
— — | 1296.22 USD — | 1310.89 USD — | — - | — — |
- {{ link.label }} {{link}}
